Clinical Trials Logo

Clinical Trial Summary

KTx recipients receiving cyclosporine-based immunosuppressive therapy, and in the opinion of the investigator would benefit from switch to a tacrolimus-based immunosuppression, will switch the immunosuppressive therapy to a tacrolimus-based one. Efficacy and safety of patients will be observed for 52 weeks.


Clinical Trial Description

The primary objective of this study is to compare the adherence of kidney transplant recipients treated with Prograf and Advagraf regimens.

The secondary objectives of this study are:

- To compare the renal function (eGFR) in KTx recipients treated with Cyclosporine and Tacrolimus regimens.

- To compare the QoL of KTx recipients treated with Cyclosporine and Tacrolimus regimens.

- To compare the efficacy of Cyclosporine and Tacrolimus regimens in KTx recipients.

- To compare the safety of Cyclosporine and Tacrolimus regimens in KTx recipients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02268201
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Terminated
Phase Phase 4
Start date July 23, 2013
Completion date March 31, 2015

See also
  Status Clinical Trial Phase
Completed NCT01336296 - Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients Phase 4
Recruiting NCT05938712 - The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Phase 2
Completed NCT00217100 - A Multivitamin Comparison Study in Kidney Transplant Recipients. Phase 3
Active, not recruiting NCT00199667 - Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients Phase 4
Terminated NCT01517984 - Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation Phase 2
Recruiting NCT04642833 - Prostate Cancer in Renal Transplants Recipients
Not yet recruiting NCT05293704 - An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients Phase 4
Completed NCT02555566 - Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study N/A
Completed NCT01782586 - Validation of Gene Expression Markers of Renal Allograft Functional Decline
Enrolling by invitation NCT02042963 - KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT) N/A
Not yet recruiting NCT05702398 - Pilot Trial of Supplemental Vitamin A and Nicotinamide Early Phase 1
Recruiting NCT05425498 - The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients N/A
Completed NCT01889758 - Pharmacokinetic Studies of Tacrolimus in Transplant Patients Phase 4
Active, not recruiting NCT03979365 - Envarsus XR Compared to Immediate Release Tacrolimus Phase 4
Recruiting NCT04965935 - Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients Phase 3
Recruiting NCT04444843 - Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen Phase 4
Completed NCT02392312 - Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
Completed NCT02639949 - Measuring and Improving Medication Adherence in Kidney Transplant Patients N/A
Withdrawn NCT02058875 - Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring Phase 4
Recruiting NCT01608412 - A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus Phase 4